Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the package: Cell-specific gene delivery using lentiviral vectors.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Molecular therapy. Oncology·2026
Same author

Septin7 is essential in early hematopoiesis, but redundant at later stages.

Life science alliance·2026
Same author

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same author

Capsid-engineered AAV vector overcomes a key intracellular barrier and efficiently transduces spiral ganglion neurons in adult mice.

Molecular therapy. Advances·2026
Same author

Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume II.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 13, 2026

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Self-inactivating alpharetroviral vectors with a split-packaging design.

Julia D Suerth1, Tobias Maetzig, Melanie Galla

  • 1Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.

Journal of Virology
|April 23, 2010
PubMed
Summary

This study developed a safer alpharetroviral vector for gene therapy. The new self-inactivating (SIN) vector minimizes risks associated with proto-oncogene activation and vector mobilization, enhancing safety for hematopoietic cell modification.

More Related Videos

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
09:12

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Published on: April 5, 2024

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
09:12

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Published on: April 5, 2024

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Area of Science:

  • Gene Therapy
  • Retroviral Vectors
  • Oncogenesis

Background:

  • Retroviral vectors for gene therapy face challenges like proto-oncogene activation and vector mobilization.
  • Alpharetroviral vectors, particularly Rous sarcoma virus (RSV)-based ones, show a more neutral integration profile.
  • Current alpharetroviral systems with intact LTRs pose risks of mobilization and immunogenicity.

Purpose of the Study:

  • To engineer a safer alpharetroviral vector system for gene therapy.
  • To reduce risks associated with intact LTRs and viral protein expression.
  • To demonstrate the efficacy of a novel self-inactivating (SIN) alpharetroviral vector.

Main Methods:

  • Development of a split-packaging system for trans-acting viral protein expression.
  • Generation of a self-inactivating (SIN) alpharetroviral vector by modifying LTRs.
  • Codon optimization of Gag/Pol expression constructs for high-titer vector production.
  • Genetic modification of murine and human hematopoietic cells.

Main Results:

  • A novel SIN alpharetroviral vector with reduced LTR transcriptional activity was created.
  • High-titer SIN vector particles were produced in human cells.
  • Successful genetic modification of hematopoietic cells was demonstrated at low multiplicity of infection.
  • The vector showed versatility for both murine and human cell modification.

Conclusions:

  • Alpharetroviral SIN vectors offer a safer alternative for gene therapy applications.
  • The developed vector system minimizes risks of insertional mutagenesis and vector mobilization.
  • This technology holds promise for the genetic modification of hematopoietic stem cells.